The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment

Investigating the Protein Signature of Adamantinomatous Craniopharyngioma Pediatric Brain Tumor Tissue: Towards the Comprehension of Its Aggressive Behavior

(2019) Claudia Martelli et al.   DISEASE MARKERS

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

(2019) LaTonya J. Hickson et al.   EBioMedicine

Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target

(2018) John R. Apps et al.   ACTA NEUROPATHOLOGICA

Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors

(2018) Nithya Krishnamurthy et al.   CANCER TREATMENT REVIEWS

Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma

(2018) Shannon Coy et al.   NEURO-ONCOLOGY

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy

(2018) Davis A. Witt et al.   PEDIATRIC BLOOD & CANCER

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma

(2017) Tobias Goschzik et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma

(2017) Andrew M Donson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma

(2017) Hermann L. Müller et al.   Nature Reviews Endocrinology

Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN

(2017) John-Paul Kilday et al.   NEURO-ONCOLOGY

Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma

(2017) Jose Mario Gonzalez-Meljem et al.   Nature Communications

Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics

(2016) Leslie C. Robinson et al.   Neurosurgical Focus

Wnt signaling in cancer

(2016) T Zhan et al.   ONCOGENE

Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma

(2016) Juan Pedro Martinez-Barbera et al.   STEM CELLS

Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles

(2016) Annett Hölsken et al.   Acta Neuropathologica Communications

Imaging Invasion: Micro-CT imaging of adamantinomatous craniopharyngioma highlights cell type specific spatial relationships of tissue invasion

(2016) John R. Apps et al.   Acta Neuropathologica Communications

Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models

(2015) Juan Pedro Martinez-Barbera et al.   JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

(2015) Priscilla K. Brastianos et al.   JNCI-Journal of the National Cancer Institute

Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma

(2015) Juan Pedro Martinez-Barbera   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

(2015) Simon J. B. Aylwin et al.   Pituitary

Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1

(2015) Yu Zhong et al.   TOXICOLOGIC PATHOLOGY

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

(2015) Priscilla K. Brastianos et al.   JNCI-Journal of the National Cancer Institute

Neuroendocrine Disorders in Pediatric Craniopharyngioma Patients

(2015) Anna Daubenbüchel et al.   Journal of Clinical Medicine

Identification of targets for rational pharmacological therapy in childhood craniopharyngioma

(2015) Jacob M Gump et al.   Acta Neuropathologica Communications

Insights into the Infiltrative Behavior of Adamantinomatous Craniopharyngioma in a New Xenotransplant Mouse Model

(2014) Christina Stache et al.   BRAIN PATHOLOGY

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas

(2014) Priscilla K Brastianos et al.   NATURE GENETICS

Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma

(2012) Cynthia L. Andoniadou et al.   ACTA NEUROPATHOLOGICA

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intracystic Therapies for Cystic Craniopharyngioma in Childhood

(2012) Ute Bartels et al.   Frontiers in Endocrinology

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up

(2011) Hermann L Müller et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling

(2010) Annett Hölsken et al.   ACTA NEUROPATHOLOGICA

The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression

(2010) Jean-Philippe Coppé et al.   Annual Review of Pathology-Mechanisms of Disease

The role of inflammation in the genesis of the cystic component of craniopharyngiomas

(2010) Benedetta Ludovica Pettorini et al.   CHILDS NERVOUS SYSTEM

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fascin Regulates Prostate Cancer Cell Invasion and Is Associated with Metastasis and Biochemical Failure in Prostate Cancer

(2009) A. D. Darnel et al.   CLINICAL CANCER RESEARCH

Effects of small interfering RNAs targeting Fascin on gene expression in oral cancer cells

(2009) Su-Feng Chen et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion

(2009) Francis Rodier et al.   NATURE CELL BIOLOGY

The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis

(2008) Frank J. T. Staal et al.   EUROPEAN JOURNAL OF IMMUNOLOGY